finance.yahoo.com ·
Guardant Health Q1 Earnings Call
Topic context
This topic has been covered 270887 times in the last 30 days across our monitored publishers.
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedGuardant Health's strong Q1 results and raised guidance reflect accelerating adoption of its liquid biopsy tests, particularly the Shield colorectal cancer test. The 48% revenue growth and 66% gross margin indicate expanding commercial traction and operational leverage. No direct supply chain or scarcity issues; the impact is company-specific and sector-wide for precision oncology diagnostics.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Q1 2026 revenue $302M, +48% YoY, fastest growth in 5 years.
- Oncology segment revenue $205M, +36% YoY, ~86,000 tests.
- Shield colorectal cancer blood test revenue $42M from ~44,000 tests, up from $6M on 9,000 tests YoY.
- FY 2026 revenue guidance raised to $1.30-$1.32B.
- Non-GAAP gross margin 66%, cash ~$1.2B, cash-flow breakeven target by end 2027.
Related stories
finance.yahoo.com
Ncmi Q1 2026 Earnings Transcript
finance.yahoo.com
Transcript Valneva Q1 2026 Earnings
finance.yahoo.com
Aytu Aytu Q3 2026 Earnings
economictimes.indiatimes.com
IPO Investors Brace for 73 Lock in Expiries Worth 34 Billion in Three Months Will Your Portfolio Be Impacted
fool.com